Dear Editor, MYH9-related disease (MYH9RD) is a rare autosomal dominant disorder caused by mutations in the gene MYH9 coding for the non-muscle myosin heavy chain IIa (myosin-9) [1] [2] [3] . The common hematologic phenotype of the disease is a congenital macrothrombocytopenia and abnormal subcellular localization of myosin-9 in neutrophils. Some of the patients develop non-hematologic manifestations like glomerulonephritis, sensorineural hearing loss, or presenile cataracts. Recent studies demonstrated a genotype-phenotype correlation in MYH9RD: Most individuals with mutations affecting the motor domain of the myosin-9 protein have severe thrombocytopenia and a high risk of developing glomerulonephritis and deafness. Instead, individuals with mutations affecting the coiledcoil rod have a milder thrombocytopenia and a lower risk for other manifestations [4] . We analyzed the MYH9 gene in five German families with suspected MYH9RD because of the presence of myosin-9 aggregates in neutrophils. Macrothrombocytopenia was asymptomatic in most of the cases and had been detected by chance in the index patients. Clinical data and molecular findings are summarized in Table 1 . Direct sequencing analysis of the MYH9 gene allowed us to identify mutations in all five families, all affecting the tail domain of myosin-9 (see Table 1 ). A novel single nucleotide deletion (c.5800delA) was detected in affected members of family 5. This mutation leads to a frameshift which deletes the last part of the region coding for the C-terminal 26 amino acids and replaces them with a new 13 amino acid segment (p.Met1934TrpfsX14). All nonsense or frameshift mutations reported so far for patients with MYH9RD are located in this region and result in a deletion of the last Cterminal residues of myosin-9. They are predicted to have a good prognosis concerning the risk of non-hematologic manifestations. In family 5, a macrothrombocytopenia was detected in the 3 years old index patient (F5-III-1) as well as in his father (F5-II-2) and grandfather (F5-I-1). The father (F5-II-2) suffered from bilateral juvenile glaucoma which led to the removal of the right eye at age 4 after retinal detachment. As an adult he developed cataract in the remaining eye. The study of Pecci et al. [4] revealed that the occurrence of cataracts in MYH9RD represents an exception to the observation of better prognosis of mutations affecting the tail domain of myosin-9-the prevalence was similar for mutations affecting the motor head domain or the tail domain, respectively. However, we cannot rule out factors independent from the MYH9 mutation as the cause of juvenile glaucoma and cataract in patient F5-II-2. Although most of the patients with MYH9RD reported here had a benign phenotype with asymptomatic macrothrombocytopenia, a correct diagnosis is important to avoid inappropriate and detrimental treatment and to carefully screen for non-hematologic manifestations which often occur later in life. Notably, two of the patients in this study have been treated with corticoids (F1-I-1, F4-II-1) and splenectomy has been recommended in one case (F1-I-1). Since a definitive prediction of the clinical course is not possible from our present state of knowledge it is necessary to regularly follow-up MYH9RD patients for the development of nephritis, hearing impairment, and cataract formation.
